崔冰，2001年毕业于中国药科大学（药理学学士），2004年毕业于中国药科大学（心血管药理学硕士），2007年于北京协和医学院药物研究所获药理学博士学位。2007年至2015年在美国加州大学圣迭戈分校（UCSD）肿瘤中心以博士后和项目科学家（Project Scientist）从事肿瘤生物学研究。2015年受聘为中国医学科学院药物研究所研究员。2016年受聘北京协和医学院博士生导师、协和学者特聘教授，2020年受聘助理教授。近年致力于肿瘤发生、转移、干性维持的分子机制及免疫治疗相关研究，累计发表54篇学术论文，其中国际核心期刊（SCI）论文49篇。近年主要学术成果（第一/通讯作者）发表在 Blood、Nat Commun、PNAS、Cancer Res等国际科学期刊。34篇合作学术成果先后发表在Cell、Cancer Cell、Immunity、JCI、Blood等国际科学期刊。

主要研究领域包括肿瘤生物学和肿瘤药理学、免疫生物学和免疫药理学、分子药理学等。具体研究方向包括以下三个方面：（1）肿瘤转移、肿瘤干性维持的分子生物学机制及药靶鉴定；（2）肿瘤干细胞、非编码RNA的肿瘤生物学作用；（3）代谢紊乱相关慢性病发病机制及药靶鉴定，主要涉及肿瘤、纤维化等疾病。

1. TRIB3 Supports Breast Cancer Stemness by Suppressing FOXO1 Degradation and Enhancing SOX2 Transcription. Yu JM*, Sun W*, Wang ZH*, Liang X, Hua F, Li K, Lv XX, Zhang XW, Liu YY, Yu JJ, Liu SS, Shang S, Wang F, Yang ZN, Zhao CX, Hou XY, Li PP, Huang B, Cui B#, Hu ZW#. Nat Commun 2019;10(1):5720.
2. Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting. Sun W*, Yang ZN*, Lin H, Liu M, Zhao CX, Hou XY, Hu ZW, Cui B#. Acta Pharm Sin B 2019; 9(5):960-972.
3. Highlights of the 2nd International Symposium on Tribbles and Diseases: Tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer. Cui B, Eyers PA, Dobens LL, Tan NS, Mace PD, Link WA, Kiss-Toth E , Keeshan K, Nakamura T, Pear WS, Feseha Y, Johnston J, Carracedo A, Scheideler M, llyas Z, Bauer RC, Erusalimsky JD, Grzesik D, Salamanca-Viloria J , Lv XX, Jin YS, Li K, Velasco G, Shang S, Lizcano JM, Zhang XW, Zhou JC, Yu JJ, Hua F, Wang F, Liu SS, Yu JM, Hu ZW#. Acta Pharm Sin B 2019;9(2):443-454.
4. Regulation of immune-related diseases by multiple factors: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences Initiative for Innovative Medicine on Tumor Immunology. Cui B, Cao XT, Zou WP, Wan YH, Wang N, Wang YH, Li PP, Hua F, Liu YY, Zhang XW, Li K, Lv XX, Huang B#, Hu ZW#. Acta Pharmaceutica Sinica B 2017 Jul;7(4):532-540.
5. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Cui B*, Ghia EM*, Chen L*, Rassenti LZ, Zhang L, Neuberg DS, Wierda WG, Keating MJ, Rai KR, Kay NE, Brown JR, Byrd JC, Gribben JG, Greaves AW, Kipps TJ#. (* co-first author) Blood 2016 Dec; 128(25):2931-2940.
6. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Zhang S*, Cui B*, Lai H, Christina W, Liu G, Widhopf GF II , Wu RR, Lao F, Schwab R, Carson D, Kipps TJ#. (* co-first author) Proc Natl Acad Sci U S A 2014 Dec; 111(48):17266-71.
7. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Cui B*, Chen L*, Chen G, Lei B, Mraz M, Salcedo M, Rassenti L, Messer M, Calin GA, Croce CM, Kipps TJ#. (* co-first author) Blood 2014 Jul; 124(4):546-54.
8. ROR1 Can Interact With TCL1 And Enhance Leukemogenesis in Eµ-TCL1 Transgenic Mice. Widhopf II GF *, Cui B*, Ghia, EM, Chen LG, Messer K, Shen ZX, Briggs SP, Croce CM, Kipps TJ#, (* co-first author) Proc Natl Acad Sci U S A 2014 Jan;111(2):793-798.
9. Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis. Cui B*, Zhang SP*, Chen LG, Yu JQ, Widhopf II GF, Fecteau JF, Rassenti LZ, Kipps TJ#, (2013) (* co-first author) Cancer Research 2013 Jun;73(12):3649-60.
10. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. Yang HZ*, Cui B*, Liu HZ, Chen ZR, Yan HM, Hua F, Hu ZW#. (* co-first author) J Immunol. 2009 Jan;182(1):692-702.
11. Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation. Zhang XW*, Zhou JC*, Peng D, Hua F, Li K, Yu JJ, Lv XX, Cui B, Liu SS, Yu JM, Wang F, Jin CC, Yang ZN, Zhao CX, Hou XY, Huang B, Hu ZW#. Autophagy. 2020 May 16(5):782-796.
12. Liu YY, Liang XY, Dong WQ, Fang Y, Lv JD, Zhang TZ, Fiskesund R, Xie J, Liu JY, Yin XN, Jin X, Chen DG, Tang K, Ma JW, Zhang HF, Yu J, Yan J, Liang HP, Mo SQ, Cheng F, Zhou YB, Zhang HZ, Wang J, Li JN, Chen Y, Cui B, Hu ZW, Cao XT, Qin XF, Huang B. Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 2018 Mar; 33(3):480-494.e7
13. Hasan MK, Yu J, Chen LG, Cui B, Shen ZX, Widhopf GF II, Rassenti LZ, Shen Z, Briggs SP, Kipps TJ#. Wnt5a Induces ROR1 to Complex with HS1 to Enhance Migration of Chronic Lymphocytic Leukemia Cells. Leukemia, 2017 Dec;31(12):2615-2622.
14. Yu J, Chen L, Cui B, Wu CC, Choi MY , Chen Y, Zhang L, Rassenti L, Widhopf GF 2nd, Kipps TJ#. Cirmtuzumab Inhibits Wnt5a-Induced Rac1 activation In Chronic Lymphocytic Leukemia Treated With Ibrutinib. Leukemia, 2017 Jun;31(6):1333-13339.
15. Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B, Yu JJ, Zhang XW, Shang S, Liu SS, Yu JM, Han MZ, Huang B, Zhang TT, Li X, Jiang JD, Hu ZW#. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. Cancer Cell. 2017 May;31(5):697-710.
16. Li PP*,#, Liu SN*, Lu M*, Bandyopadhyay G, Oh D, Imamura T, Sears D, Shen ZF, Cui B, Kong LJ, Hou SC, Liang X, Iovino S, Watkins SM, Ying W, Osborn O, Wollam J, Brenner M, Olefsky JM#. Hematopoietic-derived Galectin-3 Causes Cellular and Systemic Insulin Resistance. Cell. 2016 Nov; 167(4):973-984.e12.
17. Yu J, Chen LG, Cui B, Widhopf GF II, Shen ZX, Wu RR, Zhang L, Zhang SP, Briggs SP, Kipps TJ#. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016 Feb; 126(2):585-98.
18. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez GA, Messmer D, and Kipps TJ#. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 2014 Sep; 124(10):1637-44.
19. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ#. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Apr;110(15):6127-32. IF:9.737
20. Fecteau J, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ#. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013 Feb;121(6):971-4.

1. 《自噬—生物学与疾病 基础卷》、自噬和免疫应答（第二十七章，419-445页）、编者、科学出版社、2021年
2. Autophagy: Biology and Disease (Basic Science), Autophagy and Immune Response (Chapter 27, 595-634)、编者，Science Press, Dec 2019.
3. 《器官纤维化基础及中医药防治》，纤维化疾病的免疫学机制（第六章，171-201页）、胰腺纤维化（第十章，399-428页）、器官纤维化实验中羟脯氨酸、胶原的检测方法（第二十三章，635-649页）、编者、人民卫生出版社，2008年1月。
4. 《现代药理实验方法》，组织器官纤维化的研究方法与技术概述（第二十七篇第一章，1925-1939页）、肺纤维化实验方法和技术（第二十七篇第三章，1964-1969页）、器官纤维化实验中羟脯氨酸、胶原的检测方法（第二十七篇第十二章，2058-2069页）、编者、中国协和医科大学出版社，2012年7月。

1. 多肽PG在治疗肺纤维化中的应用，发明人：崔冰 刘姗姗 魏旭鹏 张晓伟 吕晓希。申请号：DL20210074，申请日：2021年6月21日。
2. 一种多肽PZ在治疗癌症中的应用，发明人：崔冰 刘姗姗 王婉玉 于金梅。申请号：DL20210073，申请日：2021年6月21日。
3. 六环石蒜碱衍生物、其药物组合及其制备方法和用途。发明人：潘显道，崔冰，沈珑瑛，王振贺，曾炳鏻，王旭升。申请号：DL20210062，申请日：2021年5月24日
4. 一种多肽及其在制备治疗和预防肿瘤的药物中的应用。发明人：胡卓伟，崔冰，于金梅，王振贺。申请号：CN 201910224731.7，申请日：2019年3月24日
5. 一种多肽在制备治疗和预防肿瘤的药物中的应用。发明人：胡卓伟，花芳， 余娇娇, 崔冰，周丹丹。申请号：2017101309321，申请日：2017年3月9日。
6. Cancer Treatment Combinations. Kipps TJ, Chen LG, Cui B、US 62/355,171, filed on 27 Jun, 2016, US 2017/0368173 A1, files on 28 Dec, 2017, US 10,688,181B2, filed on 27 Jun, 2017, authorized on 23 Jun, 2020
7. Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis. Kipps TJ, Yu J, Cui B, Chen LG, George WF, Prussak C, US 9,758,591B2, WO2014031174A1, PCT/US2013/032572, filed on 15 Mar 2013, authorized on 12 Sep, 2017. (Develop anti-ROR1 antibody Cirmtuzumab. Phase 2 Clinical Trial is Initiated in March, 2017)
8. Therapeutic antibodies against ROR-1 protein and methods for use of same. Kipps TJ, George WF, Cui B, US 9,217,040 B2, WO2012/097313A2, PCT/US2012/021339, filed on 13 Jan 2012, authorized on 12 Dec, 2015. US 9,523,695 B2, filed on 4 Sep 2012, authorized on 20 Dec, 2016. US 9,933,434 B2, filed on 7 Nov 2016, authorized on 3 Apr, 2018
9. 胡卓伟，严君，何令帅，崔冰，杨红振，谢文杰，李平平，TLR4和TLR9激动剂复方在抑制肿瘤转移中的应用，发明专利专利号CN 101134046 B，授权日期 2011年10月5日。
10. 胡卓伟，杨红振，崔冰 等. 抗Toll样受体2抗体抑制肿瘤转移的用途，发明专利专利号：CN 101147803 B,申请日2006年9月21日，授权日2012年7月11日。
11. Hu ZW, Ke CK, Cui B, Yang HZ, Liu YY, Chen L, Guo XJ. Composition and its use. CN 100450492 C, filed on 1 Jul 2005, authorized on 14 Jan, 2009. 胡卓伟，柯传奎，崔冰 等. 一种组合物及其应用, 发明专利专利号：CN 100450492 C，

1. 2016、教育部高等学校科学研究自然科学优秀成果奖、二等奖（排名6）
2. 2013、美国肿瘤协会AACR第104届年会Millennium学者奖
3. 2006、卫生部第九届医药卫生青年科技论坛三等奖